Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication (Scientific Reports (2017) 7 (40920) DOI: 10.1038/srep40920);The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Sacramento, Carolina Q ^a,b   De Melo, Gabrielle R ^a,b   De Freitas, Caroline S ^a,b   Rocha, Natasha ^a,b   Hoelz, Lucas Villas Bôas ^b   Miranda, Milene ^a,c   Fintelman Rodrigues, Natalia ^a,b   Marttorelli, Andressa ^a,b   Ferreira, André C ^a,b   Barbosa Lima, Giselle ^a,b   Abrantes, Juliana L ^a,b,c   Vieira, Yasmine Rangel ^a,b   Bastos, Mônica M ^b   De Mello Volotão, Eduardo ^a   Nunes, Estevão Portela ^b   Tschoeke, Diogo A ^c   Leomil, Luciana ^c   Loiola, Erick Correia ^d   Trindade, Pablo ^d   Rehen, Stevens K ^c,d   Bozza, Fernando A ^a,b   Bozza, Patrícia T ^a   Boechat, Nubia ^b   Thompson, Fabiano L ^c   De Filippis, Ana M B ^a   Brüning, Karin ^e   Souza, Thiago Moreno L ^a,b   more..

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^e Karin Bruning and Cia Ltda   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE; SOFOSBUVIR; VIRAL PROTEIN;

ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS GENOME; VIRUS REPLICATION; ZIKA FEVER; ZIKA VIRUS;

ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; DNA-DIRECTED RNA POLYMERASES; GENOME, VIRAL; HUMANS; MUTATION; SOFOSBUVIR; VIRAL PROTEINS; VIRUS REPLICATION; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85010023391     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46772     Document Type: Erratum

References (50)

1. Musso, D. & Gubler, D. J. Zika Virus. Clin Microbiol Rev 29, 487-524 (2016).
2. Musso, D. et al. Potential sexual transmission of Zika virus. Emerg Infect Dis 21, 359-361 (2015).
3. Dick, G. W. , Kitchen, S. F., Haddow, A. J. & Zika virus, I. Isolations and serological specifcity. Trans R Soc Trop Med Hyg 46, 509-520 (1952).
4. Cerbino-Neto, J. et al. Clinical Manifestations of Zika Virus Infection, Rio de Janeiro, Brazil, 2015. Emerg Infect Dis 22 (2016).
5. Faria, N. R. et al. Zika virus in the Americas: Early epidemiological and genetic fndings. Science 352, 345-349 (2016).
6. Solomon, T., Baylis, M. & Brown, D. Zika virus and neurological disease-approaches to the unknown. Lancet Infect Dis 16, 402-404 (2016).
7. Calvet, G. et al. Detection and sequencing of Zika virus from amniotic fuid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 16, 653-660 (2016).
8. Cao-Lormeau, V. M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531-1539 (2016).
9. Chutaputti, A. Adverse efects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 15, E156-163 (2000).
10. Delvecchio, R. et al. Chloroquine inhibits Zika Virus infection in diferent cellular models. BioRxiv, 10.1101/051268 (2016).
11. Zmurko, J. et al. The Viral Polymerase Inhibitor 7-Deaza-2′ -C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Negl Trop Dis 10, e0004695, 10.1371/journal. pntd.0004695 (2016).
12. Eyer, L. et al. Nucleoside inhibitors of Zika virus. J Infect Dis 214, 707-711 (2016).
13. Barrows, N. J. et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe 20, 259-270 (2016).
14. Elfky, A. A. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol 88, 2044-2051 (2016).
15. Xu, M. et al. Identifcation of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 22, 1101-1107 (2016).
16. Piperno, A., Cordaro, M., Scala, A. & Iannazzo, D. Recent highlights in the synthesis of anti-HCV ribonucleosides. Curr Med Chem 21, 1843-1860 (2014).
17. Bhatia, H. K., Singh, H., Grewal, N. & Natt, N. K. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother 5, 278-284 (2014).
18. Sacramento, C. Q. et al. The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication. BioRxiv, 10.1101/061671 (2016).
19. Souza, T. M. L. et al. Inhibition of HSV-1 replication and HSV DNA polymerase by the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid and its aglycone. Antiviral Research 77, 20-27 (2008).
20. Hottz, E. D. et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-infammasome activation. Blood 122, 3405-3414 (2013).
21. Lu, J. et al. The IFITM proteins inhibit HIV-1 infection. J Virol 85, 2126-2137 (2011).
22. Tan, B. H. et al. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216, 317-325 (1996).
23. Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816-818 (2016).
24. Gasteiger, E. et al. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 31, 3784-3788 (2003).
25. Dutta, S. et al. Data deposition and annotation at the worldwide protein data bank. Mol Biotechnol 42, 1-13 (2009).
26. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234, 779-815 (1993).
27. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Tornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26, 283-291 (1993).
28. Eisenberg, D., Lüthy, R. & Bowie, J. U. VERIFY3D: assessment of protein models with three-dimensional profles. Methods Enzymol 277, 396-404 (1997).
29. Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863-864 (2011).
30. Zhang, J., Kobert, K., Flouri, T. & Stamatakis, A. PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 30, 614-620 (2014).
31. Schmieder, R. & Edwards, R. Fast identifcation and removal of sequence contamination from genomic and metagenomic datasets. PLoS One 6, e17288, 10.1371/journal.pone.0017288 (2011).
32. Nurk, S. et al. Assembling single-cell genomes and mini-metagenomes from chimeric MDA products. J Comput Biol 20, 714-737 (2013).
33. Huang, X. & Madan, A. CAP3: A DNA sequence assembly program. Genome Res 9, 868-877 (1999).
34. Malet, H. et al. Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J Biol Chem 282, 10678-10689 (2007).
35. Lu, G. & Gong, P. Crystal Structure of the full-length Japanese encephalitis virus NS5 reveals a conserved methyltransferase-polymerase interface. PLoS Pathog 9, e1003549, 10.1371/journal.ppat.1003549 (2013).
36. Zhao, Y. et al. Molecular basis for specifc viral RNA recognition and 2′ -O-ribose methylation by the dengue virus nonstructural protein 5 (NS5). Proc Natl Acad Sci USA 112, 14834-14839 (2015).
37. Appleby, T. C. et al. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science 347, 771-775 (2015).
38. Ferron, F. , Bussetta, C., Dutartre, H. & Canard, B. The modeled structure of the RNA dependent RNA polymerase of GBV-C virus suggests a role for motif E in Flaviviridae RNA polymerases. BMC Bioinformatics 6, 255, 10.1186/1471-2105-6-255 (2005).
39. Onorati, M. et al. Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia. Cell Rep 16, 2576-2592 (2016).
40. Brasil, P. et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report. N Engl J Med 4, 10.1056/ NEJMoa1602412 (2016).
41. Driggers, R. W. et al. Zika Virus Infection with Prolonged Maternal Viremia and Fetal Brain Abnormalities. N Engl J Med 374, 2142-2151 (2016).
42. Rasmussen, S. A., Jamieson, D. J., Honein, M. A. & Petersen, L. R. Zika Virus and Birth Defects - Reviewing the Evidence for Causality. N Engl J Med 19, 1981-1987 (2016).
43. Smith, D. W. & Mackenzie, J. Zika virus and Guillain-Barré syndrome: another viral cause to add to the list. Lancet 387, 1486-1488 (2016).
44. Gilead. Product Monograph Pr SOVALDI® (sofosbuvir) Tablets 400 mg sofosbuvir Antiviral Agent http://www.gilead.ca/pdf/ca/ sovaldi-pm-english.pdf (2015; acessed on 09/12/2016).
45. Zhong, L. et al. Quantitative proteomics study of the neuroprotective efects of B12 on hydrogen peroxide-induced apoptosis in SH-SY5Y cells. Sci Rep 6, 22635, 10.1038/srep22635 (2016).
46. Guo, D., Zhu, Q., Zhang, H. & Sun, D. Proteomic analysis of membrane proteins of vero cells: exploration of potential proteins responsible for virus entry. DNA Cell Biol 33, 20-28 (2014).
47. Guo, H. C. et al. Quantitative Proteomic Analysis of BHK-21 Cells Infected with Foot-and-Mouth Disease Virus Serotype Asia 1. PLoS One 10, e0132384, 10.1371/journal.pone.0132384 (2015).
48. De Clercq, E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev 33, 1249-1277 (2013).
49. Day, C. W. et al. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 67, 38-45 (2005).
50. Leyssen, P. , De Clercq, E. & Neyts, J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol 69, 1461-1467 (2006).